FYERS
Home
/
Stocks
/
Profit Loss
/
Shukra Pharmaceuticals Profit & Loss

Shukra Pharmaceuticals Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Jun 2025Mar 2025Dec 2024
₹24 Cr₹6 Cr₹39 Cr₹5 Cr₹13 Cr₹11 Cr
₹54 L₹95 L₹82 L₹1 Cr₹1 Cr₹1 Cr
₹24 Cr₹7 Cr₹40 Cr₹7 Cr₹15 Cr₹12 Cr
₹5 Cr₹7 Cr₹13 Cr₹5 Cr₹7 Cr₹7 Cr
₹20 Cr₹2 Cr₹28 Cr₹2 Cr₹9 Cr₹5 Cr
₹43 L₹26 L₹28 L₹27 L₹27 L₹15 L
₹18 Cr₹38 L₹27 Cr₹1 Cr₹8 Cr₹4 Cr
₹13 Cr-₹2 Cr₹20 Cr₹1 Cr₹5 Cr₹3 Cr

Share Price Live Stats

Open (₹)53.01
Volume (₹)5.71 L
High (₹)55.50
Upper Circuit62.40
Low (₹)52.28
Lower Circuit41.60
Prev Close52.00
52W High (₹)65.26
Price52.90
52W Low (₹)26.18

Share Market Cap & Key Ratios Overview

M.Cap (₹)2292.09 Cr
Div. Yield (%)0.02
PE Ratio63.59
Debt to Equity0.07
Price to Book15.23
Book Value1.44
EPS (TTM)0.82
Face Value1.00
ROE (%)15.90

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMA-ANSE
DIVISLAB-ANSE
TORNTPHARM-ANSE
ZYDUSLIFE-ANSE
CIPLA-ANSE
LAURUSLABS-ANSE
LUPIN-ANSE
MANKIND-ANSE
DRREDDY-ANSE
AUROPHARMA-ANSE
SHUKRAPHAR-BNSE
LTP
1W Low
1W High
Market cap (₹)
1903.8-16.3 (-0.85%)
1900.10
1964.85
4,56,833Cr
9184.7-84.3 (-0.91%)
9051.85
9296
2,45,426Cr
4874.85-160.15 (-3.18%)
4866.10
5049
1,87,320Cr
1133.8-53.2 (-4.48%)
1126
1191.45
1,13,217Cr
1383.65-34.35 (-2.42%)
1377
1426.20
1,12,212Cr
1857.95-77.35 (-4.00%)
1812
1947.90
1,01,155Cr
2122.25-52.75 (-2.43%)
2117.80
2209
97,626Cr
2344.05-43.35 (-1.82%)
2323.15
2407.40
96,859Cr
1161.95-15.85 (-1.35%)
1155
1179.90
96,406Cr
1653.3+3.3 (0.20%)
1623.05
1706.70
93,614Cr
52.9+8.62 (19.47%)
44.26
55.50
2,292Cr

Key Highlights of Shukra Pharmaceuticals Ltd’s P&L

In 2025-03-31, Shukra Pharmaceuticals Ltd reported total revenue of ₹32.59Cr, compared with ₹74.57Cr in 2024-03-31, reflecting Shukra Pharmaceuticals Ltd turnover.

Depreciation was ₹3Cr and finance costs were ₹59.49Lakh in 2025-03-31

Profit Before Tax (PBT) has been ₹13.34Cr in 2025-03-31 as compared to ₹19.88Cr in 2024-03-31.

Net Profit (PAT) was ₹9.58Cr in 2025-03-31 compared with ₹18.54Cr in 2024-03-31.

Earnings per share (EPS) were ₹0.22 in 2025-03-31, compared with ₹16.94 in 2024-03-31.